Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Newsome SD, Kieseier BC, Arnold DL, Shang S, Liu S, Hung S, Sabatella G
J Neurol. 2016 Jun 17. Epub 2016 Jun 17. PMID: 27314959.Abstract
